Goldman Sachs Group Inc Larimar Therapeutics, Inc. Transaction History
Goldman Sachs Group Inc
- $706 Billion
- Q2 2025
A detailed history of Goldman Sachs Group Inc transactions in Larimar Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 131,622 shares of LRMR stock, worth $560,709. This represents 0.0% of its overall portfolio holdings.
Number of Shares
131,622
Previous 2,671,271
95.07%
Holding current value
$560,709
Previous $5.74 Million
93.38%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding LRMR
# of Institutions
126Shares Held
65.9MCall Options Held
4.83MPut Options Held
83.7K-
Deerfield Management Company, L.P. (Series C) New York, NY21.2MShares$90.4 Million1.41% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.05MShares$25.8 Million0.38% of portfolio
-
Blue Owl Capital Holdings LP New York, NY4.93MShares$21 Million7.71% of portfolio
-
Opaleye Management Inc. Boston, MA4.11MShares$17.5 Million2.84% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.66MShares$15.6 Million0.01% of portfolio
About Larimar Therapeutics, Inc.
- Ticker LRMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,269,200
- Market Cap $184M
- Description
- Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...